Helius Medical Technologies Inc. [NASDAQ: HSDT] gained 16.91% on the last trading session, reaching $0.31 price per share at the time. The company report on November 14, 2022 that Helius Medical Technologies, Inc. Reports Third Quarter 2022 Financial Results.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
— Total Q3 revenue up 80% over prior year —- Cash on hand expected to fund operations through 2023 —- Company to host call at 8:30am today –.
Helius Medical Technologies Inc. represents 28.20 million in outstanding shares, while the company has a total market value of $9.35 million with the latest information. HSDT stock price has been found in the range of $0.255 to $0.3098.
If compared to the average trading volume of 659.98K shares, HSDT reached a trading volume of 3275794 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Helius Medical Technologies Inc. [HSDT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HSDT shares is $3.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HSDT stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Noble Capital Markets have made an estimate for Helius Medical Technologies Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 24, 2021.
The Average True Range (ATR) for Helius Medical Technologies Inc. is set at 0.04, with the Price to Sales ratio for HSDT stock in the period of the last 12 months amounting to 11.69. The Price to Book ratio for the last quarter was 0.20, with the Price to Cash per share for the same quarter was set at 0.55.
Trading performance analysis for HSDT stock
Helius Medical Technologies Inc. [HSDT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 25.58. With this latest performance, HSDT shares gained by 4.59% in over the last four-week period, additionally sinking by -73.75% over the last 6 months – not to mention a drop of -94.10% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HSDT stock in for the last two-week period is set at 59.36, with the RSI for the last a single of trading hit 66.10, and the three-weeks RSI is set at 54.43 for Helius Medical Technologies Inc. [HSDT]. The present Moving Average for the last 50 days of trading for this stock 0.2748, while it was recorded at 0.2496 for the last single week of trading, and 1.1896 for the last 200 days.
Helius Medical Technologies Inc. [HSDT]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Helius Medical Technologies Inc. [HSDT] shares currently have an operating margin of -3472.03 and a Gross Margin at +4.60. Helius Medical Technologies Inc.’s Net Margin is presently recorded at -3473.56.
Return on Equity for this stock declined to -239.73, with Return on Assets sitting at -175.62.
Helius Medical Technologies Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 14.70 and a Current Ratio set at 15.20.
An analysis of insider ownership at Helius Medical Technologies Inc. [HSDT]
There are presently around $0 million, or 5.20% of HSDT stock, in the hands of institutional investors. The top three institutional holders of HSDT stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 304,564, which is approximately 556.813% of the company’s market cap and around 4.01% of the total institutional ownership; BLACKROCK INC., holding 255,381 shares of the stock with an approximate value of $79000.0 in HSDT stocks shares; and CITADEL ADVISORS LLC, currently with $22000.0 in HSDT stock with ownership of nearly 390.191% of the company’s market capitalization.
12 institutional holders increased their position in Helius Medical Technologies Inc. [NASDAQ:HSDT] by around 700,545 shares. Additionally, 4 investors decreased positions by around 87,662 shares, while 8 investors held positions by with 28,504 shares. The mentioned changes placed institutional holdings at 816,711 shares, according to the latest SEC report filing. HSDT stock had 4 new institutional investments in for a total of 59,521 shares, while 3 institutional investors sold positions of 87,554 shares during the same period.